Form 4: Vaxcyte CEO Grant Pickering Sells Shares Under 10b5-1 Trading Plan

Vaxcyte CEO Grant Pickering sold shares of the company's common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Grant Pickering, CEO of Vaxcyte, Inc., reported the sale of common stock on May 1, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• A total of 2,516 shares were sold in multiple transactions at prices ranging from $60.76 to $63.87.
• Following the reported transactions, Pickering directly owns 477,847 shares of common stock.
• Additionally, 146,054 to 146,682 shares are held indirectly through children's trusts.
• The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating stock sales by an insider. The sales were conducted under a pre-arranged trading plan, suggesting no immediate negative implications. The sentiment is neutral.

Industry Context

Sales by executives are a normal part of corporate governance. It is important to note that the sales were executed under a pre-arranged 10b5-1 trading plan, which is a common practice to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but the pre-arranged nature of the sales mitigates potential concerns.
• The sales do not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates